KYMR - Company ID 0001815442
The table below shows Kymera Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $357.01M | $120.26M | $109.97M | $68.39M | $47.98M | $31.00M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | $0.00 | $15.00M | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $871.21M |
| $510.27M |
| $405.32M |
| $419.42M |
| $451.27M |
| $302.34M |
| Property, plant & equipment | $43.17M | $50.46M | $48.13M | $13.33M | $11.88M | $10.84M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.74B | $978.03M | $575.76M | $603.13M | $605.90M | $487.18M |
| Accounts payable | $4.01M | $5.99M | $7.08M | $4.33M | $4.00M | $4.37M |
| Total current liabilities | $83.21M | $67.77M | $85.69M | $71.34M | $92.54M | $110.62M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $163.15M | $142.42M | $180.79M | $112.98M | $146.27M | $203.29M |
| Retained earnings | -$1.07B | -$754.61M | -$530.75M | -$383.79M | -$228.98M | -$128.76M |
| Total equity | $1.58B | $835.62M | $394.97M | $490.15M | $459.64M | $283.89M |